Ensoma Inc.’s lead program, EN-374, has been granted orphan drug and rare pediatric disease designations by the FDA for the treatment of X-linked chronic granulomatous disease. Ensoma anticipates ...

Using skin, lung, and blood samples from sarcoidosis ... and the director of Penn's Cutaneous Sarcoidosis & Granulomatous ...